MEDIA RELEASE PR38140
Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals
MELBOURNE, Feb. 1/Medianet International-AsiaNet/ --
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a new agreement with
Eli Lilly and Company (NYSE: LLY) under which Starpharma's dendrimer drug delivery technology will be applied
to enhance compounds in Lilly's human pharmaceutical portfolio.
Under the terms of the agreement Lilly will fund a collaborative research and development program with the aim
of creating improved drugs incorporating SPL's proprietary delivery technology, to be commercialised by Lilly.
The agreement announced today relates to the delivery of certain human pharmaceuticals, and is separate and
additional to the contract signed in May 2009 in which it was agreed that Starpharma and Elanco (Lilly's animal
health division) would work together to develop new animal health products with enhanced properties. The Elanco
collaboration continues in its own right.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by
applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for
some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer
technology for pharmaceutical, life-science and other applications. Products based on SPL's dendrimer technology
are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements
with various partners.
In the pharmaceutical field Starpharma is developing VivaGel® as a vaginal microbicide and condom coating and
has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to
control where and when drugs go when introduced to the body) and Diagnostics. More broadly the company is
exploring dendrimer opportunities in materials science applications including water remediation.
For further information:
Media
Buchan Consulting
Kyahn Williamson
Tel: +61 3 9866 4722
Mob: +61 401 018 828
kwilliamson@bcg.com.au
Ellie Papathanasiou
Tel: +61 2 9237 2800
epapathanasiou@bcg.com.au
Starpharma
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
Ben Rogers
Company Secretary
+61 3 8532 2702
ben.rogers@starpharma.com
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma's business, which can be
identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project",
"believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could
provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such
forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance or achievements expressed or implied
by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's
and other health authorities' requirements regarding any one or more product candidates nor can there be any
assurance that such product candidates will be approved by any health authorities for sale in any market or that
they will reach any particular level of sales. In particular, management's expectations regarding the approval and
commercialization of the product candidates could be affected by, among other things, unexpected clinical trial
results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions
or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general; government, industry, and general public pricing pressures;
and additional factors that involve significant risks and uncertainties about our products, product candidates,
financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary materially from those described herein as
anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this
document and does not assume any obligation to update any forward-looking statements contained in this
document as a result of new information, future events or developments or otherwise.
SOURCE: Starpharma
NEWS 
